People receiving weight-loss drug Wegovy sustained weight loss for up to four years, shedding an average of 10% of their body weight in that time, as per a new study. Wegrovy is a brand that markets semaglutide injections, that have gained widespread attention for their weight-loss effects. The study also found that Semaglutide injections boost an individual's heart health, even when weight loss doesn't take place.

The study, called SELECT, was published in journal Nature Medicine. "At four years, we see ongoing benefits of semaglutide," said Cheng-Han Chen, MD, interventional cardiologist from Cardiologist, who was not involved in the research. Besides the weight loss, it also lead to a loss in cardiovascular outcomes.

The research was conducted on 17000 adults, who had obesity but did not have diabetes. Overall, people who received once-weekly injections of semaglutide lost on average 10.2% of their body weight over the course of four years. All of the study participants continued to lose weight for about 65 weeks, a year and three months, and then their weight remained at a stable level.

Were There Any Side Effects?

However, people's experience with the medication varied. Researchers found no unexpected safety issues with drug during trial. In fact, most the people who withdrew from the study were those who experienced the known symptsoms of the semaglutide injections like nausea, indigestion etc. This occurred mainly during the beginning of the study, as the dose of the medicine is increased to a maximally tolerated dose.

What Did The Results Say?

Of the people on the highest dose of Wegovy, 68% lost at least 5% of their body weight. This compared to 21% of people on the placebo. Additionally, of the total people on Wegovy about 23% lost at least 15% of their body weight. For those in the placebo group, only 1.7% lost that much body weight.

Semaglutide Shows Heart Benefits Beyond Weight Loss

Researchers found that even individuals who did not experience significant weight reduction while on the drug saw a reduced risk of major heart events. Recent analysis of the SELECT trial data revealed that semaglutide significantly lowers the risk of heart attack, stroke, and cardiovascular-related deaths in adults with obesity or those who are overweight. Notably, the results of this study lead the US FDA to approve Novo Nordisk's Wegovy for reducing heart-related risks in this group.

What Is Semaglutide?

Semglutide is the synthetic version of GLP-1—a natural hormone produced in the intestines that regulates blood sugar, appetite, and digestion. Now, every time you eat, your body produces various hormones, including GLP-1. These are called Post nutrition hormones, and help you absorb the energy you just consumed. GLP-1 travels to your pancreas, prompting it to produce insulin. It also travels to the hypothalamus in your brain, which gives you the feeling of being full or satiated. Ozempic imitates this hormone, thereby, silencing the food chatter in the brain. Interestingly, for some people this food chatter is really quiet ( people with low appetite) and for others it is an outburst, (people who generally binge eat.) So with Ozempic, silencing this self-talk in the brain, people tend to lose their appetite and eventually weight.

Are Their Any Side Effects Of Semaglutide?

Semaglutide, marketed under the brand name Wegovy, is primarily an antidiabetic medication used to treat Type 2 diabetes. It is also an anti-obesity drug used for long-term weight management. While it can be taken as a subcutaneous injection or orally, it has significant side effects. It primarily impacts your gastrointestinal tract and its side effects include constipation, nausea, abdominal pain, diarrhoea, and fatigue amongst others.

India, which carries the world's second-largest population of hemophilia cases—a genetic blood disorder—must shift towards prophylaxis care for the bleeding disorder, said health experts today on the occasion of World Hemophilia Day.

World Hemophilia Day is observed every year on April 17 to raise global awareness of hemophilia and other inherited bleeding disorders.

This year’s theme of “Diagnosis: First step to care” highlights the critical importance of diagnosis—the essential first step in treatment and care.

According to the World Federation of Hemophilia (WFH), 75 percent of people suffer from hemophilia, without even knowing it, simply because they don’t have access to basic healthcare.

What Is Hemophilia?

Hemophilia is a rare bleeding disorder where blood does not clot properly, even for minor injuries. It is caused by an error in a specific gene on the X chromosome, leading to a deficiency or absence of clotting factors.

While the condition mainly affects males, women are the genetic carriers. In people with hemophilia, the blood lacks sufficient clotting factors -- which are proteins essential for stopping bleeding.

Whether the bleeding is external, such as cuts, or internal, such as bleeding into joints or muscles, the blood does not clot. So, it can be a very serious disorder.

Without consistent care, repeated bleeding into joints can lead to

• chronic pain,
• deformity,
• loss of mobility.

Hemophilia is mainly of three types:

• Hemophilia A: This is the most common type. People with this condition have low levels of clotting factor 8 (factor VIII).
• Hemophilia B: People with this type don’t have enough clotting factor 9 (factor IX).
• Hemophilia C: Also known as factor 11 (factor XI) deficiency. It’s the least common type of hemophilia.

The Burden Of Hemophilia In India

Hemophilia A, the most common type, affects about 1 in 5,000 male births, underscoring the urgent need for improved detection and awareness.

Hemophilia B, on the other hand, is an X-linked genetic disorder affecting 1 in approximately 25,000 male births.

India bears a significant burden from Hemophilia A. Estimates suggest around 136,000 individuals are affected, but only a small fraction are diagnosed and registered due to unequal access to essential care.

Dr. Varun Kaul, Professor, Dept of Pediatrics, Guru Gobind Singh Medical College & Hospital, Faridkot, told HealthandMe that in India, systemic gaps, ranging from limited diagnostic access to unevenly distributed treatment centers, continue to restrict access to RRT, especially beyond metro cities.

In contrast, more than 50 per cent of persons with hemophilia globally benefit from regular replacement therapy (RRT) as the standard of care.

Routine replacement therapy (RRT), commonly known as prophylactic care or prophylaxis, is the standard treatment for severe hemophilia.

It involves the regular intravenous (IV) infusion of clotting factor concentrates to maintain factor levels above 1 per cent to prevent spontaneous bleeding, particularly into joints and muscles.

Need For Prophylaxis Care For Hemophilia

Most Indian patients currently rely on reactive, on-demand therapy to manage bleeds after they happen.

Dr. Kaul said that although this may help prevent the immediate crisis, it fails to stop the cumulative joint damage that often results in permanent disability.

“Providing regular, scheduled infusions to maintain sufficient clotting factor levels can prevent bleeds entirely, reducing annual bleed rates by 90 per cent and enabling a life free from chronic pain and constant fear of the next bleed,” Dr. Kaul said.

Some progress is visible, as States like Karnataka, Kerala, Jammu and Kashmir, to name a few, have pioneered state-sponsored RRT programs.

“It is now imperative to transition from mere crisis management toward implementing preventive care as a National Health priority,” Dr Kaul added.

Hemophilia: The Need To Focus On Women

Dr Rahul Bhargava, Principal Director & Chief - Hematology, Hemato-Oncology & Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram, stressed the importance of focusing the treatment on females.

"Carrier testing in hemophilia remains largely focused on affected males, while women who may be carriers are often not included in routine screening,” Dr Bhargava told HealthandMe.

As an X-linked inherited disorder, hemophilia can present in women with low clotting factor levels, leading to

• prolonged bleeding,
• heavy menstrual cycles,
• complications during surgery and childbirth.

Most of the cases remain undiagnosed until a clinical event occurs.

"Identifying carriers through timely testing enables appropriate counselling and informed reproductive decisions. It also supports early diagnosis in families and reduces the risk of severe bleeding complications in future generations,” the doctor said.

How To Manage Hemophilia?

Dr Tulika Seth, Professor of Haematology at All India Institute of Medical Sciences (AIIMS) in New Delhi, in a post on social media platform X, stressed the importance of testing for hemophilia.

"If a child gets prolonged bleeding from a minor cut or injury, or if there are spontaneous painful swellings in the joints after minor falls, or sometimes even by somebody holding the baby, or there's a lot of bruising, people should get the baby tested or the adult tested for hemophilia," Dr. Seth said.

She noted that in mild cases of hemophilia, sometimes a person may not be aware that they have a deficiency, and then when they go for a tooth extraction or any surgery, they may have a problem.

"So, it's important to know your family history, and if you've had any prolonged bleeding after any pain, then you should tell your doctor and get tested," the doctor said.

Dr Bhargava also called for a broader approach that includes women in screening programs to help strengthen prevention and long-term management of hemophilia across families.

Hemophilia management requires attention beyond hospital care to prevent long-term complications.

To reduce bleeding episodes, it is important to:

• regularly follow up,
• adhere to treatment,
• maintain joint health.

Other measures include

• safe physical activity,
• balanced nutrition,
• avoiding trauma

"Integrating medical treatment with lifestyle practices supports functional independence and improves overall disease control,” Dr. Bhargava told HealthandMe.

Hemophilia is a rare genetic bleeding disorder, usually inherited, wherein blood cannot clot properly due to low levels of clotting factors, causing prolonged bleeding or spontaneous internal hemorrhages.

Symptoms include easy bruising, joint pain/swelling, and excessive bleeding. While not curable, it is treated with factor replacement therapy and gene therapy.

India has the world's second-largest population of hemophilia patients, with estimates suggesting over 70,000 to over 1,36,000 cases of Hemophilia A and B. However, while around 13,000 to 19,000+ patients are registered, many remain undiagnosed.

This World Hemophilia Day, Dr. Sheikh Bilal, Head of Department, Pathology, Government Medical College, Srinagar, Kashmir, exclusively told Healthandme that the primary reason why thousands of Indians remain undiagnosed and unable to access proper care is due to budget constraints, lack of awareness among policymakers, and the need for technocrats to advocate boldly for regular replacement therapy.

Despite having the second-largest hemophilia population, only 9-10 percent receive treatment as compared to 80-100 percent in some European countries.

The expert explained: "Money plays an important role. Every center in India has, at their own level, their own policymakers and the people who are at the helm of affairs. We are the second home for the hemophilia and we can change the lives of these people by having the regular replacement but it is all depending upon the perception of individual centers."

He also noted that the government needed to introduce policy reforms endorsing regular replacement therapy as the gold standard to help ensure equitable access to patients.

The median age at diagnosis for severe hemophilia in India stands at 60 months—five full years—compared to under 12 months in high-income countries. This delay is not just a matter of time but one that poses a risk of serious clinical consequences. Late diagnosis often means repeated, unmanaged bleeding episodes during early childhood, particularly into joints, before appropriate treatment begins.

Early Warning Signs

The three types of this condition include :

• Hemophilia A: This is the most common type. You may develop this condition because you have low levels of clotting factor 8 (factor VIII).
• Hemophilia B: You may have this type if you don’t have enough clotting factor 9 (factor IX).
• Hemophilia C: Hemophilia C is also known as factor 11 (factor XI) deficiency. It’s the least common type of hemophilia.

Recognizing the early warning signs can be critical in preventing long-term complications. Symptoms such as recurrent nosebleeds, heavy menstrual bleeding in females, and prolonged bleeding after minor injuries are often overlooked or dismissed. Common signs include:

• Bleeding into the joints. This can cause swelling and pain or tightness in the joints. It often affects the knees, elbows, and ankles.
• Bleeding into the skin (which is bruising).
• Bleeding into the muscle and soft tissue, which can cause a build-up of blood in the area (called a hematoma).
• Bleeding of the mouth and gums, including bleeding that is hard to stop after you lose a tooth.
• Bleeding after circumcision.
• Bleeding after having shots, such as vaccinations.
• Bleeding in the head of an infant after a difficult delivery.
• Blood in the urine or stool.
• Frequent and hard-to-stop nosebleeds.

The condition is much more common in people who were born male since they can get it with a change to the gene on one X chromosome. People who have a family history of hemophilia are also at higher risk.

Treatment Options

The treatments for haemophilia have never been more effective, but they work only for patients who have been diagnosed. In a condition where every missed bleed moves a joint closer to permanent damage, the most important clinical act is also the most basic one: recognition.

The main treatment for severe hemophilia involves replacing the clotting factor you need through a tube in a vein. This replacement therapy can be given to treat a bleeding episode in progress. It can also be given on a regular schedule at home to help prevent bleeding episodes. Some people receive continuous replacement therapy.

Replacement clotting factor can be made from donated blood. Similar products, called recombinant clotting factors, are made in a laboratory, not from human blood.

For many people, a normal weight brings a sense of reassurance. If the weighing scale looks fine, health is assumed to be in check. However, in clinical practice, we are increasingly seeing individuals who are not overweight yet show clear signs of fatty liver. This condition, often called lean fatty liver, is quietly becoming more common in India and is a major public health concern.

Dr Harshavardhan Rao B, HOD & Consultant, Department of Gastroenterology, Ramaiah Memorial Hospital, while talking about the possibility of people suffering from a lean fatty liver, despite normal body weight, answered all FAQs regarding the condition.

What is Lean Fatty Liver?

When fat accumulates in the liver of individuals who have a normal body mass index (BMI), it is referred to as "lean fatty liver." It falls under the broader category of metabolic dysfunction-associated steatotic liver disease (MASLD), but it occurs in people who do not fit the prototypical profile of being overweight with high sugar levels and uncontrolled blood pressure. It is also more common in younger age groups compared to the typical MASLD patient. This contradicts the general belief that a normal body weight and BMI are indicators of good metabolic health and, by extension, optimal liver function.

Why Are We Seeing More of It in India?

Metabolic diseases are presenting differently in the Indian population. Even individuals who appear lean may carry underlying metabolic risk. Several patterns are worth noting:

1. Diets high in refined carbohydrates—polished white rice, bakery products, packaged snacks
2. Low physical activity, particularly in urban, desk-bound settings (exacerbated in the post-COVID era)
3. Visceral abdominal fat accumulation (fat deposited around the internal organs) despite a normal overall weight
4. Diet quality and meal patterns tend to matter more than total intake
5. Abnormal sleep patterns (night shifts, doom-scrolling at night, Netflix marathon trends)
6. Chronic high-stress environments

Lean fatty liver produces no obvious symptoms in the early stages. Most individuals feel entirely well. The diagnosis is typically incidental—picked up during routine health check-ups when liver enzymes are mildly elevated or when an ultrasound shows fatty changes.

The absence of warning signs has two potentially serious downstream effects. Firstly, most cases are diagnosed at a later stage when liver damage has already set in, and secondly, it makes it easy to defer action since the patient perceives no discomfort and does not feel the need to prioritise this over routine work and personal stresses.

Why Normal Weight Can Be Misleading

Body weight does not give the full picture of metabolic health. A normal BMI can coexist with:

1. High visceral fat around internal organs
2. Reduced skeletal muscle mass
3. Borderline or elevated fasting blood glucose
4. Dyslipidaemia or abnormal cholesterol metrics

This forms the basis for the clinical category of “metabolically unhealthy, normal weight."

Less Talked About Contributors

Beyond the standard risk factors, several contributors tend to be underappreciated:

1. Irregular meal timing, including skipped meals and late-night eating
2. Poor sleep and sustained stress, both of which affect hormonal and metabolic regulation
3. Long-term use of certain medications
4. Low dietary protein, which can reduce muscle mass and impair metabolism
5. Vitamin D and B12 deficiencies, which are common in this population

Together, these factors can have profound effects on metabolic health and eventually lead to fatty liver and even long-term liver damage.

What Should Be Done?

The management of lean fatty liver focuses on metabolic improvement rather than weight reduction.

1. Balanced meals over calorie restriction
2. Reduced intake of refined carbohydrates and added sugars
3. Adequate dietary protein to preserve muscle mass
4. Regular physical activity — both aerobic and resistance-based (40%–60%)
5. Consistent meal timings; avoiding heavy meals late at night
6. Routine monitoring of blood glucose, lipid profile, and liver enzymes, not just body weight

For many Indians — including those who do not see themselves as being at risk — this distinction matters. Identifying and acting on relevant lifestyle factors early is worthwhile. At this stage, fatty liver is often reversible with sustained dietary and behavioural changes.